Overview

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Exenatide through collecting, reviewing, identifying and verifying the safety and effectiveness information about Exenatide in general practice.
Details
Lead Sponsor:
AstraZeneca
Treatments:
Exenatide